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Aim: The aim of this review was to better understand the risks and care issues associated with poorly 
managed type 2 diabetes mellitus, in relation to poor prognosis of bipolar disorder. 
Methods:
diabetes” OR “Insulin Resistance” AND “Bipolar Disorder” AND “Outcome” AND “Course of 
illness” in a variety of databases. The publications were all filtered following pre
Results:
type 2 diabetes, there was association of 
with the severity of the bipolar disorder. Individuals with bipolar disorder and diabetes mellitus 
experienced neurodegenerative disorders with more depressive symptoms. Additionally, higher rate of 
non-compliance was identifi
Conclusions:
both diabetes mellitus and neuropsychiatric disorders. There is a 
psychiatric and general medical providers. 
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INTRODUCTION 
 
Background 
 
The National Institute of Clinical Excellence (NICE) defines 
Bipolar Disorder (BD) as a lifelong, disabling condition which 
is categorised by episodes of mania and hypomania
consists of “abnormally elevated mood or irritability and 
related symptoms with severe functional impairment or 
psychotic symptoms”, defined as bipolar I (BD
is characterised by “periods of abnormally low mood which 
relate to symptoms with decreased or increased function for 
four days or more”, this is defined as bipolar II (BD
Anderson, Haddad, and Scott conducted a worldwide survey, 
which found several countries had a median onset at the age of 
25 and overall lifetime prevalence of 0.6% for BD
0.4% for BD-II2. Medical comorbidities are responsible for the 
early mortality rates in BD. The mortality rateis higher 
amongst patients diagnosed with manifestations of the 
metabolic syndrome (obesity and diabetes, cardiovascular 
illnesses). The highest risk factor is the onset of diabetes 
mellitus(DM); many studies identified approximately two
higher mortality rate in BD with multi-morbidity compared to 
the general population3. 
 
Growing evidence supports the existence of a link between BD 
and DM and suggests “shared risk factors and disease 
mechanisms”4. Type 2 diabetes mellitus (T2DM) isa chronic 
illness, which frequently goes undiagnosed for many years 
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 A systematic review of the literature was conducted using combined terms “Type 2 
 Nine primary articles were selected. The analysis showed that in patients diagnosed with 
higher uncontrolled bipolar 
ed with the use of bipolar disorder medications.       
 Overall results indicated an overlapping clinical pathophysiology relationship between 
 
. This is an open access article distributed under the Creative Commons Attribution License, 
1.  Mania 
-I). Hypomania 
-II)2. 
-I, with 
-fold 
because the hyperglycaemia develops gradually.  At early 
stages it is often not sufficiently severe for the patient to notice 
any of the classic symptoms of diabetes.  It carries increased 
risks of a range of complications
people with schizophrenia or BD is two to three times higher 
than in the general population. Am
mental illness, 9.9% and 11.3% had T2DM. In addition, this 
was identified with causal relationships in overlapping 
functional disturbances affecting regions of the brain which 
contribute to manic episodes6
prevalence amongst T2DM patients
implications for self-care and care for those working in 
diabetes and psychiatry services
 
In recent literature reviews on this topic, Calkin 
Charles, Lambert and Kerner4
co-morbidities, imposed disease
other, which appeared substantial, impacting both treatment 
response and outcome. However, they 
large-scale studies on the late onset of
available literature lacked large sample sizes and longitudinal 
data4.McIntyre et al. reviewed 
studies and based upon the outcomes, recommended a 
management plan with baseline observations at referral to 
provide a reference point9. Pendlebury and Holt (2010) made 
similar recommendations7. 
 
 
 
 
 
 
 
-defined criteria. 
symptoms period corresponding 
 
need for collaborative care among 
 
 
 
5. The prevalence of T2DM in 
ongst patients with severe 
. This suggests that the high 
 of BD has clinical 
7. 
et al.8 and 
raisedthe possibility that these 
-modifying effects on each 
were unable to evaluate 
 BD, and reported that 
cross-sectional and longitudinal 
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Overall, these comorbidities appear associated with a severe 
course of the mental illness, reduced quality of life, and 
premature mortality10. This has led to recommendations that 
focused attention is required, to improve diagnosis, treatment, 
management, and outcome4. 
  
Aim 
 
This systematic review explored recently published cross-
sectional, observational and randomised controlled studies. 
The primary objective was to examine the risks associated 
with poorly managed T2DM, in relation to, association with, 
or causation of, BD. Secondly; to examine the long-term care 
provided for co-existing T2DM with BD. Consideration was 
also given to the identification of any strategies in place to 
manage the risk of worsening BD.  
 
Study Question 
 
Why do patients experience a different outcome for BD when 
diabetes mellitusis present?  
 
METHODS 
 
A systematic search was conducted using combined 
terms;“Type 2 diabetes” OR “Insulin resistance” AND 
“Bipolar Disorder” AND “Outcome” AND “Course of illness” 
in a variety of databases using ScienceDirect, PubMed and 
Cochrane library for papers published between January 2002 
and December 2017. The search revealed a total of 3,127 
articles, in which 40 publications were found in PubMed, 
2,255 in Summons, 611 in ScienceDirect and 221 in Cochrane 
library. Potential articles were then screened by titles and 
abstracts and narrowed down to a total number of 76 
publications after removal of replications. Articles were 
included if they were observational, cross-sectional or 
randomised, had a pre-defined sample size, participants were 
above the age of 16 years, had been diagnosed of T2DM, and 
diagnosed with a BD of any type using DSM VI or V and/or 
ICD-10. Articles were excluded if participants were diagnosed 
withtype-1 diabetes or if the article was published in language 
other than English language, was a systematic review or meta-
analysis.A total of nine publications were identified to meet 
the relevant criteria, as well as strong supporting evidence to 
effectively meet the aim of the review. 
 
RESULTS 
 
The results from the review are summarised in (Table 1).The 
nine studies that were identified in this review consisted of 
three cohort studies, four cross-sectional studies and two 
randomised trials.  
 
Insert table 1 here 
 
Quality of selected studies 
 
All studies reported information on the methodologies, and all 
used a quantitative approach.  They had detailed thoroughly 
their methods and their discussion of the results was of high 
quality. These studies included within the review, followed a 
pattern, in the sampling methods used (Table 2). 
 
Chronic course and Elevated episodes 
 
In the recent cross-sectional study by Calkin (n=121)>50% of 
the participants had insulin resistance or T2DM11. Those 
patients with T2DM had 3-fold higher odds of a chronic course 
of BD and 3 fold higher odds of rapid cycling when compared 
to euglycemic patients. This was supported by another review 
which evaluated several cross-sectional and longitudinal 
studies associated with common underlying mechanisms 
between the disorders9. Ruzickova et al.compared several 
studies on the clinical features of BD with or without 
T2DMusing a cross-sectional design12. The study compared 26 
patients with comorbidity of T2DM to 196 patients without 
T2DM; all patients were diagnosed with BD. It was suggested 
that disability with poor overall functioning was present in 
patients with T2DM. However, there were limitations to this 
study; there was an age difference between the participants 
with comorbid T2DM and those without. McIntyre et al. 
conducted an international retrospective study with a large 
sample size, which found an association of a more complex 
illness presentation and less favourable outcome within BD 
patients when comorbidity with T2DM is present13.  
 
Mansur et al. conducted a cross-sectional study, in patients 
with BD, to investigate the moderating effects of impaired 
glucose metabolism (IGM) on variables of illness and severity 
of BD14.Their outcomes also suggested that patients with IGM 
had an earlier onset of BD, with longer duration of illness 
experienced and higher ratio of manic and hypomanic to 
depressive episodes. Overall the results suggested a possible 
accelerating disease course in the IGM subpopulation. The 
study consisted of 55 patients with BD, of which only 8 
individuals had been diagnosed withT2DM, so is not readily 
generalised. A high proportion of women were recruited in the 
study of Sylvia et al. which could potentially indicate some 
link with biochemical differences in genders14.In a 12.5-year 
observational study, it was again identified that patients with 
T2DM among patients with BD had a higher hospital mortality 
rate and experienced more complications15. Evidence from a 
recent review by Buoli, Serati and Altamura supported the 
association of rapid cycling BD with severe biological 
abnormalities and revealed that participants within the studies 
had signs of increased damage to DNA and presented with 
more endocrine dysregulation16. Although this review found 
potential and actual candidate biomarkers, most of the studies 
included, used wide inclusion criteria and open-label design 
which limited heterogeneity. Subsequently, they found rapid 
cycling to worsen the course of BD, however, the sample was 
limited, and obesity was high in this cohort of 
participants17.Although obesity and impaired glucose tolerance 
is prevalent in patients with BD who currently take 
antipsychotics, it has been suggested that these factors are 
present within these individuals before taking these 
medications6. In support of this, it was discovered that the use 
of multiple drugs can affect the overall course of illness in 
BD17.Furthermore, some recent studies evaluated biomarkers 
such as oxidative stress and adiponectin in patients diagnosed 
with both BD and IGM. It was shown that these disorders had 
a negative impact on the illness course with low values of 
these biomarkers signifying an increased number of 
episodes18,19. 
 
A recent clinical study on the metabolic syndrome and adverse 
clinical outcomes in patients with BD studied 143 stable 
outpatients aged 18-65 performing fasting biochemical 
assessments to investigate the prevalence of metabolic 
syndrome20. Bai et al. found that patients with BD and T2DM 
had more adverse clinical outcomes than those without; 
including more hospitalisations, poorer insight, poorer global 
function and more impaired executive functioning.  
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However, alimitation was that only 10 individuals out of all 
participants had T2DM, which indicates a poor representation 
of the population in relation to the outcomes assessed. In 
addition the cognitive function and clinical examinations were 
assessed by the author. In comparison, Sylvia et al. conducted 
a randomised multi-site study of the medical burden in BD, for 
a comparative trial of lithium or quetiapine for six months14. 
The research conducted consisted of 482 participants with BD-
I and BD-II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only 6.2% of the overall participants had T2DM, which 
supported evidence that hypertension is the most common 
manifestation of the metabolic syndrome found in patients 
diagnosed with BD14,20. Patients with T2DM along with 
common metabolic disorders had a higher prevalence in older 
ages but had less severe manic symptoms. This outcome could 
be related to a link between metabolic disorders and 
depression. The study indicated that those using lithium in 
comparison to quetiapine had lower overall rates of depression 
Table 1 Evidence for effects associated with type 2 diabetes mellitus (DM) prevalence and poor management in bipolar 
disorder (BD) 
 
Author Title 
Type of 
study 
Types of Bipolar 
Disorder 
Types of Diabetes 
Mellitus 
Method of 
evaluation 
Participants  
Age (Years) 
Population (n) 
of BD 
participants 
Results for both BD and T2DM 
Calkin et 
al. 2015 
Insulin resistance and 
outcome in bipolar disorder 
Cohort 
Bipolar type 1 and 
2 
Type 2 diabetes mellitus 
and insulin resistance 
Maritime 
bipolar registry 
> 18 
 
121 
50% and 48.7% of BD patients 
with DM and IR had a chronic 
course of illness, 38.5% and 39.5% 
of DM and IR patients had higher 
rates of rapid-cycling than 
euglycemic, 36.8% and 36.7% of 
DM and IR patients more likely to 
be refractory to lithium 
Hajek et al. 
2014 
Insulin resistance, diabetes 
mellitus and brain structure in 
bipolar disorder 
Cross-
sectional 
Bipolar type 1 and 
2 
Type 2 diabetes mellitus 
and insulin resistance 
Maritime 
bipolar registry 
> 18 
 
33 with insulin 
resistance, 26 
without 
Smaller hippocampal volume in BD 
patients with IR or T2DM 
Ruzickovae
t al. 
2003 
Clinical features of bipolar 
disorder with and without 
comorbid diabetes mellitus 
Prospecti
ve 
Bipolar type 1 and 
2 or other 
Type 2 diabetes mellitus 
Maritime 
bipolar registry 
> 18 
Average age = 
52.5 with DM 
and BD 
26 diabetics 
196 non-
diabetics 
11.7% of DM prevalent in the 
population 
Higher rates of rapid cycling. The 
more chronic course of BD with 
DM, Patients scored lower on 
global assessment of functioning 
scale 
Bai et al. 
2016 
Metabolic syndrome and 
adverse clinical outcomes in 
patients with bipolar disorder 
Clinical 
cohort 
Bipolar disorder 
type 1 and 2 
Type 1 or 2 diabetes 
mellitus 
Psychiatric 
outpatient in a 
university 
hospital 
16-65 143 
BD patients had 29.4% prevalence 
of a metabolic syndrome. Those 
who had a metabolic syndrome had 
more previous hospitalisations, 
poorer global function, and more 
impaired executive function 
Mansur et 
al. 2016 
Impaired glucose metabolism 
moderates the course of 
illness in bipolar disorder 
Cross-
sectional 
Bipolar disorder 
any type 
Impaired glucose 
metabolism or type 2 
diabetes mellitus 
Outpatient unit 
> 18 
Average age = 
42.85 with DM 
and BD 
55 
IGM and DM patients had an 
earlier age of onset of BD, 
Longer illness duration and a 
higher ratio of manic/hypomanic to 
depressive episodes 
Kemp et al. 
2010 
Medical comorbidity in 
bipolar disorder: the 
relationship between illnesses 
of the endocrine/metabolic 
system and treatment 
implications 
Randomis
ed 
double-
blinded 
and open-
label 
Bipolar disorder 
type 1 and 2 
Type 2 diabetes mellitus 
University 
medical care 
center 
18-65 225 
Illness of the endocrine/metabolic 
system correlated with depressive 
symptoms. With A 1-unit increase 
in BMI, response decreased 7.5% 
to lithium and valproate 
Sylvia et al.
2015 
Medical burden in bipolar 
disorder: findings from the 
clinical and health outcomes 
initiative in comparative 
effectiveness for bipolar 
disorder study (Bipolar 
CHOICE) 
Randomis
ed 
Bipolar disorder 
type 1 and 2 
Type 1 and 2 diabetes 
mellitus 
Medical 
database 
18-68 482 
Early age of onset of BD 
symptoms, lower chance of 
cardiometabolic conditions. 
Although more time spent 
depressed, longer duration of 
illness for DM patients, particularly 
females 
Mansur et 
al. 2016 
Brain-derived neurotrophic 
factor, impaired glucose 
metabolism, and bipolar 
disorder course 
Open-
label 
Bipolar disorder 
type 1 and 2 
Impaired glucose 
metabolism and type 2 
diabetes mellitus 
Outpatient unit >18 83 
In adjusted models for IGM and 
T2DM patients, lower levels of 
BDNF were found and more 
psychiatric hospitalisations, suicide 
attempts and number of previous 
mood episodes associated 
Hajek et al. 
2015 
Type 2 diabetes mellitus: A 
potentially modifiable risk 
factor for neurochemical brain 
changes in bipolar disorder 
Cross-
sectional
= 4.57, 
p=0.06 
Bipolar disorder 
type 1 and 2 
Type 2 diabetes mellitus 
Maritime 
bipolar registry 
>18 59 
Levels of N-acetyl aspartate were 
lowest in DM patients compared to 
euglycemic 
 
 
Table 2 Summary of included reviews 
 
Articles Sampling Dropouts Age Interview method and location 
Hajek et al., 2014 Purposive  Not reported  Reported  Not reported  
Ruzickova et al., 2003 Purposive  Not reported  Reported  Not reported  
Bai et al., 2016 Purposive  Not reported  Reported  Not reported  
Mansur et al., 2016b Purposive  Not reported  Not reported Not reported  
Calkin et al., 2015 Convenience  Reported  Reported Not reported  
Mansur et al., 2016a  Convenience  Reported  Not reported Not reported  
Hajek et al., 2015 Random Not reported  Reported  Not reported  
Sylvia et al., 2015 Random  Reported Reported  Not reported  
Kemp et al., 2010  Random  Reported  Reported  Not reported  
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and mania on average. The limitation of this study was that the 
information collected was assessed at a single time point. 
 
Brain Abnormalities 
 
Both type 1 and 2 DM are associated with a variety of central 
nervous system complications including distorted brain 
imaging, increased rates of cognitive decline, the risk of 
neurodegenerative diseases and depression. Although 
alterations in insulin signalling leads to complications, these 
are poorly recognised21. In T2DM, hyperglycaemia and 
hyperinsulinemia activate proteins involved in the insulin 
signalling pathways, facilitating insulin resistance22. A study 
by Liu et al. found that due to the protein content, insulin 
activity in the brain and signalling pathways are decreased in 
T2DM which leads to overactivation of GSK-3β and 
downregulation of insulin receptors in the brain, leading to 
neurodegeneration and impaired cognitive function in the 
long-term23. In a recent study, Mansur et al. measured and 
compared plasma levels of the biomarker Brain-Derived 
Neurotrophic Factor (BDNF) in individuals with BD and 
within healthy controls, to assess the moderating effect of 
IGM24. The study carried out was a randomised study, which 
consisted of 83 patients across both active and controls. They 
found that individuals with BD had lower levels of BDNF, 
which indicates that IGM may modify the relationship between 
the course of BD and the biomarker readings. Furthermore, the 
study found that the levels of BDNF were related to lifetime 
depressive episodes, psychiatric hospitalisations and suicide 
attempts. The sample size in this study was small and it used 
cross-sectional design. Fujinami et al. found similar results 
suggesting that aging is a factor that influences serum BDNF 
levels25.  
 
Hajek et al. conducted a cross-sectional study, on 59 BD 
patients26. They found that T2DM damages the hippocampus, 
causing atrophy; however, this was identified as being 
preventable. The methodology of the study included 
interviews, performed by clinicians and was reviewed in a 
blinded fashion. It was found that the group of BD patients 
with T2DM had a smaller hippocampal volume. The results 
provided evidence that diabetes care amongst BD patients can 
be improved. In a similar study, Hajek also attempted to 
understand the brain structure changes with IGM and T2DM. 
In their later observational study, readings indicated that BD 
patients had the lowest N-acetyl aspartate levels and total 
creatine, providing evidence of neurochemical alterations, 
indicating poorer functioning and clinical outcome in patients 
with these co-morbidities27. Once again, on average BD 
patients with co-morbid T2DM experienced more 
hospitalisations, longer duration of illness and higher history 
of psychotic symptoms, but overall, a lower number of 
illnesses over the study period compared to other BD patients. 
It was found that the association with elevated neurochemical 
alterations originated from IGM changing to T2DM. There 
were several limitations to both studies; the cross-sectional 
design limited associations being made between T2DM and 
brain structure. There were also some strengths; the 
biochemical evaluation, which assessed both T2DM and BD 
together with other clinical information allowing control for 
potential confounders.  
 
Song found that a group of patients with metabolic syndrome 
showed a significant reduction in mean cortical thickness and 
volume in both brain hemispheres compared with control 
studies indicating that neurodegenerative processes, due to 
metabolic syndrome, are present even in the preclinical stage 
when compared to patients with BD28.Yates et al., reviewed 
several studies and identified a correlation between these 
metabolic disorders and brain function29. Although within 
these studies, differences in the population demographics, ages 
and gender explained lack of consistency throughout their 
findings. 
 
It was identified that in the older patient, cognitive impairment 
may interfere with psychosocial functioning in BD patients 
compared to younger patients30. In support, Schouws et al., 
conducted a study to examine the neuropsychological 
functioning in a group of 119 elderly patients with early and 
late onset BD compared to a control group of 78 patients 
without BD31. The findings included BD patients scoring the 
lowest on almost all the cognitive measures used. The 
limitations were that the actual age of participants and the 
medications they used were not indicated. The late-onset 
participants were more impaired in psychomotor performances 
than the early-onset patients. Conversely, Beavers found no 
relationship between decline in cognitive function and high 
HbA1c readings. In agreement32 Musenreviewed the previous 
literature and found no group effects on brain structure or 
cognition decline with T2DM alone33.  
 
Treatment Refractory 
 
An association between poor treatment response and outcome 
was noted in patients with BD and metabolic disorders. Calkin 
et al., observed 80 BD patients receiving a trial of lithium for 
6-months, to assess for a response to treatment using the Alda 
scale11. The study found patients with Insulin Resistance (IR) 
and T2DMwere refractory to lithium treatment. However, the 
6-month period of assessment was too short to confirm the 
validity of this finding. Similarly, Kemp et al. examined,in an 
open-label study, the relationship between the medical burden 
of BD in 225 patients taking lithium and valproate for rapid-
cycling presentations of BD34. The results showed that in 
patients who were receiving lithium and valproate, 
individualswithT2DM, had a greater risk of depression and 
poorer treatment outcomes. It was hypothesised that a possible 
mechanism in insulin resistance and T2DM, is that patients 
experience chronic peripheral hyperinsulinemia, which has 
been linked to down regulation of insulin receptors within the 
blood-brain barrier, to restrict the insulin channel to the 
brain35. 
 
Kemp et al. (2010) identified “that for every 1 unit increase in 
BMI over 23, the chances of response to treatment is decreased 
by 7.3%”34.The limitations of this study, was that rapid-
cycling BD was only treated with lithium and valproate in 
combination and was not compared to another comparative 
drug.  
 
Unsatisfactory Diabetes Care 
 
It is suggested that only a fraction of individuals with BD seek 
treatment15and this the lack of treatment is known to lead to a 
chronic, difficult to treat condition and poor quality of life10. In 
addition, easier admission to private hospitals was shown to 
increase the BD patients’admission rate when compared to 
general hospitals and primary care trusts15.This was supported 
by Sullivan,et al. in a database retrospective study; the authors 
found that out of 4,275 visits byT2DM patients hospitals 
across America, only 136 visits were made by persons with 
comorbid psychotic disorders. In those 136 patients, a direct 
International Journal Of Current Medical And Pharmaceutical Research, Vol. 4, Issue, 04, pp.3253-3261, April, 2018 
 
 3257
link was found in relation to poor self-management due to 
psychiatric disorders and need for emergency care36.  
 
Winkley et al. found poor attendance at diabetes education 
sessions amongst mental health patients (20%)37. Goldberg et 
al. found poorly documented access to medical care by those 
who had mental illnesses due to social and environmental 
factors38. In support, it was found that patients with severe 
mental illnesses may have poor access to general healthcare, 
with fewer opportunities for cardiovascular risk screening and 
poor prevention schemes available, in comparison to non-
psychiatric groups39. 
 
An earlier study by Dixon et al. compared HbA1c levels in 200 
patients with T2DM and schizophrenia with major mood 
disorders, to a control group of 100 patients with severe mental 
illness40. The results were surprising, as findings suggested 
that patients with severe mental illnesses across the three 
groups had lower HbA1c levels in comparison to those without 
mental illnesses, however there was no data specific to BD 
patients.  
 
A group of T2DM patients with mental illnesses was recruited 
from number of mental health centres, and compared to a 
group recruited from primary care trusts, regarding their ability 
to self-care. HbA1c and knowledge about diabetes were poorer 
in patients treated in mental health centres than in those in 
primary care41. Nevertheless, the study did not control other 
health-related features, such as the use of medications, which 
can adversely affect outcomes. This study was not randomised. 
 
Considering that BD has elements of depressive mood, the 
findings of Shin et al.42 and Lunghi et al.43 may be applicable. 
Shin reported that individuals with different types of 
depression had impaired problem-solving abilities which may 
have accounted for poor self-management42.This was 
supported by Lunghi et al. looking at medication adherence in 
patients taking anti-diabetics within two groups of patients; 
one included patients diagnosed with depression and the other 
patients without a depression diagnosis. Within the study, 52% 
participants in the first group experienced non-adherence to the 
drugs compared to 49% of participants in the second group43. 
This suggests that depression was an independent risk factor 
for anti-diabetic non-adherence. Similar findings came from a 
study by Gonzalez, which found low adherence to dietary 
intakes such as fruits and vegetables, and poor exercise and 
foot care44. 
 
Integrated Care 
 
It is suggested that a “stronger integration of medical and 
psychiatric care could help prevent the negative effects of 
these co-occurring disorders on the long-term outcome of 
patients with BD”4. Supporting this, Coventry et al. conducted 
a cluster-randomised trial to test the effectiveness of an 
integrated collaborative care model for patients with long-term 
mental and physical comorbidities. They concluded that the 
integration of low-intensity psychological treatment with 
primary care can improve self-management in the short term 
but required the practitioners to be trained to deliver the 
integrated service45. Similarly, Chwastiak et al. demonstrated 
the probability of successful implementation of a collaborative 
care program for poorly controlled T2DM patients in the urban 
community within primary care clinics using a retrospective 
cohort design46. A total of 151 patients with mental disorders 
including BD, using the program, had a decrease of 
0.9mmol/molin HbA1c levels vs. a 0.2 mmol/moldrop in 483 
patients who did not attend the program. This suggested that 
integration of collaborative healthcare is a promising strategy 
for chronic disease management. It was acknowledged that 
poor assessment of patients with mental illnesses such as BD 
causes challenges such as patients not being able to recall the 
hypo – or hyperglycaemia episodes they experienced. Often, 
symptoms are mistaken for other psychiatric illnesses leading 
to misdiagnosis47. 
 
In respect of care for BD, Kilbourne et al. conducted a 
randomised controlled trial to examine a psychological care 
model in comparison with medical care model48. Fifty eight 
participants were recruited of whom, 27 received BD care 
based on the psychological model and the rest received care 
based on the medical model. There was a significant difference 
in physical health, with evidence of a decline in quality of life 
in the psychological model group after 6-months compared to 
those treated under the medical model where improvements 
were shown. When using the medical model of care, specific 
care goals were set, including recognition of the mania and 
depressive episodes and changeovers, identification of triggers 
and improvement of coping strategies such as setting diet and 
exercise goals. Additional aspects were considered in 
depressive episodes such as suicide prevention and follow up 
on treatment adherence48.  
 
Pharmacological Management 
 
Bennett et al. focused on identifying the benefits and harms of 
antidiabetic medications such as metformin, sulfonylureas, 
thiazolidinediones, dipeptidyl peptidase-4 inhibitors and 
glucagon-like peptide 1 receptor agonists; as mono- and 
combined therapies in T2DM adults49. The results from this 
study showed that all the anti-diabetic medications used had 
broadly similar efficacy, in reducing levels of HbA1c by 1 
percent over the course of the study as a monotherapy. In 
comparison, Metformin had a higher percentage of HbA1c 
reductions. In support, Wahlqvist et al. evaluated whether anti-
diabetic medications were a pre-cursor for affective disorders 
including BD50. Follow-up studies followed a large-scale 
cohort (n= 800,000) of Taiwanese subjects over 50 years of 
age. The results identified that the combination of both 
sulfonylureas and metformin reduced the risk of worsening BD 
in T2DM, regardless of gender. The use of a large cohort study 
was considered as study strength, however, the study did not 
factor for the severity of diabetes within the individuals as they 
were recruited from a database.  
 
The recent a 6-week randomised double-blinded trial by 
Zeinoddini et al. which evaluated safety and efficacy of 
pioglitazone in patients diagnosed with T2DM or metabolic 
syndrome with BD comorbidity; found that patients who took 
pioglitazone experienced an improvement in their depressive 
symptoms51. However, no physical assessment was 
undertaken, and accordingly it was difficult to determine if the 
drug was reliable in treating the diabetes to establish 
relationship between the improvement of diabetes control and 
the improvement of depressive symptoms. Oliveira et al., 
found that there was a significant improvement in depressive 
symptoms and physical functioning with the use of insulin 
leading to a reduction in HbA1c, however, there were few 
significant differences found in BMI and disease 
complications52.In addition, a systematic review described how 
anti-diabetic medication had neurophysiological benefits, 
helping with both T2DM and long-term BD outcomes. The 
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author stated that specifically, thiazolidinediones were more 
effective in comparison tometformin53.  
 
Non-Pharmacological Management 
 
McIntyre et al., specified that a complete evaluation of patients 
with BD should be carried out, as well as an assessment of 
both behavioural and medical factors9. These assessments 
include eating disorders; tobacco use, illicit drugs use or 
alcohol consumption, thyroid dysfunctions, T2DM (HbA1c) 
and obesity (baseline body weight). In support, a randomised 
trial was recently conducted on 5,145 patients diagnosed with 
T2DM and BD, over 10 years.  It examined the effects of 
intensive lifestyle intervention in comparison to medications 
alone. A considerable reduction in frequency was found for 
mild or more severe depressive symptoms (Beck Depression 
Inventory score >10) within these patients, in comparison to 
medications alone. A limitation found in this study was that 
quality of life was not assessed, which could have adversely 
affected the outcome of results54.The daily intake of fruits, 
vegetables, whole grains and unsaturated fatty acids was found 
to be beneficial55. 
 
Evidence has found that regular physical exercise allows the 
body to reduce plasma glucose levels, by increasing the uptake 
of glucose into skeletal cells55. Kuyci et al. conducted a recent 
review of studies on the enhancement of treatment outcomes in 
patients with BD by incorporating aerobic exercise56. The 
results showed an array of links between effects on 
neurocognitive functions, neurotransmitter systems and insulin 
sensitivity across diverse ages, gender and populations. 
However, the intensity of exercises and the risk of 
precipitating a manic episode vs the benefit in depressive 
episode was not studied. Similarly, Sylvia, Ametrano and 
Nierenberg identified that those healthy individuals who 
participated in regular exercise interventions, had an 
association with increases in BDNF57. In addition, Conn et al. 
(2014) found through a meta-analysisa moderate improvement 
in HbA1c levels
58.  
 
A study by Ng, Dodd and Berk, investigated the effectiveness 
of a walking programme in acute BD, it was found that small 
changes in stress- and depression-related scores were 
identified from participants compared to non-participants59. 
This provided support for a therapeutic indication for mild 
physical activity in the acute treatment of BD 
 
In support, it was discussed by Wright et al.,that it is important 
for clinicians to ensure patients are aware of positives and 
negatives that may arise during physical exercise 
interventions60. In contrast, it was concluded within a recent 
study by Sorkin et al. that clinicians should accentuate the 
importance of identifying and treating mental health issues to 
guide in prescribing appropriately in patients with T2DM61.   
 
LIMITATIONS OF THE REVIEW 
 
A common limitation found across the studies was the use of 
cross-sectional design; this limited the significance, as it 
contributed to a higher level of bias, since associations 
between the intervention and control groups could not be 
established. Using perspective or observational designs would 
provide a better approach towards detecting associations, and 
can be used as an alternative to interpreting data as causal 
relationships. The publication dates of literature analysed 
covered a 15-year span and a number of countries. These 
factors allowed for disparities amongst the findings, as the 
healthcare systems, screening equipment, and techniques, as 
well as the diagnostic criteria, were different. The medications 
being used within the studies may have affected the results 
observed; in addition, high rates of depression were identified 
across several studies which were represented as an 
intervention group in comparison to bipolar disorder as there 
was limited literature available. This may not have beena 
suitable representation of patients in this population. 
 
CONCLUSION 
 
In conclusion, due to the considerable burden associated with 
BD, the need for integrated care has been highlighted. Positive 
outcomes can be achieved. The optimal use of anti-diabetes 
medications, good diet and mild physical activity can improve 
both disorders. Overall, a suggestion for the use of future 
closer monitoring within this population is appropriate to 
recognise early signs and prevent the onset of T2DM in BD 
patients. However, it is clear that further longitudinal studies 
are required, focussing on assessing future therapeutic 
approaches in the population with BD and T2DM comorbidity 
to improve their health outcomes.   
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